Total Payments
$40,331
2019 Payments
$322.78
Companies
10
Transactions
32
Medicare Patients
28
Medicare Billing
$4,244
Payment Breakdown by Category
Research$31,434 (77.9%)
Consulting$6,535 (16.2%)
Travel$1,719 (4.3%)
Food & Beverage$641.85 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31,434 | 10 | 77.9% |
| Consulting Fee | $6,535 | 1 | 16.2% |
| Travel and Lodging | $1,719 | 7 | 4.3% |
| Food and Beverage | $641.85 | 14 | 1.6% |
Payments by Type
Research
$31,434
10 transactions
General
$8,896
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $28,212 | 8 | $0 (2018) |
| Shire North American Group Inc | $6,535 | 1 | $0 (2017) |
| Lupin Inc. | $3,000 | 1 | $0 (2018) |
| AstraZeneca UK Limited | $1,237 | 6 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $905.00 | 8 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $237.58 | 2 | $0 (2019) |
| Genentech USA, Inc. | $144.40 | 3 | $0 (2017) |
| CSL Behring | $26.70 | 1 | $0 (2018) |
| Circassia Pharmaceuticals Inc | $19.22 | 1 | $0 (2017) |
| Bio Products Laboratory, Inc. | $14.22 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $322.78 | 3 | Teva Pharmaceuticals USA, Inc. ($222.51) |
| 2018 | $20,947 | 11 | Glenmark Pharmaceuticals Inc. ($16,684) |
| 2017 | $19,061 | 18 | Glenmark Pharmaceuticals Inc. ($11,528) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/14/2019 | Teva Pharmaceuticals USA, Inc. | Fluticasone Propionate and Salmeterol (Drug) | — | Cash or cash equivalent | $222.51 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma • Category: Respiratory | ||||||
| 01/22/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.11 | General |
| 01/21/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $82.16 | General |
| 10/02/2018 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: Immunology | ||||||
| 07/25/2018 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $8,713.80 | Research |
| 07/11/2018 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,970.00 | Research |
| 05/23/2018 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,000.00 | Research |
| 05/21/2018 | Lupin Inc. | ADVAIR (Drug) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 01/11/2018 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $811.72 | General |
| 01/11/2018 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $110.46 | General |
| 01/11/2018 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $106.61 | General |
| 01/11/2018 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $83.36 | General |
| 01/11/2018 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $83.13 | General |
| 01/11/2018 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $41.43 | General |
| 12/14/2017 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $28.08 | General |
| 11/14/2017 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $539.20 | General |
| 11/14/2017 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $94.23 | General |
| 11/14/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 11/14/2017 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $52.65 | General |
| 11/14/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $30.57 | General |
| 10/26/2017 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: Immunology | ||||||
| 05/30/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: GSP301-304 | ||||||
| 05/12/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: GSP301-304 | ||||||
| 05/09/2017 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $122.40 | General |
| 04/24/2017 | Shire North American Group Inc | HYQVIA (Biological) | Consulting Fee | Cash or cash equivalent | $6,535.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $11,528 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $3,000 | 1 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $222.51 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 28 | 158 | $15,648 | $4,244 |
Total Patients
28
Total Services
158
Medicare Billing
$4,244
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 15 | 71 | $12,152 | $3,351 | 27.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 13 | 87 | $3,496 | $892.94 | 25.5% |
About Dr. Gregory Gottschlich, MD
Dr. Gregory Gottschlich, MD is a Specialist healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1720080807.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Gottschlich, MD has received a total of $40,331 in payments from pharmaceutical and medical device companies, with $322.78 received in 2019. These payments were reported across 32 transactions from 10 companies. The most common payment nature is "" ($31,434).
As a Medicare-enrolled provider, Gottschlich has provided services to 28 Medicare beneficiaries, totaling 158 services with total Medicare billing of $4,244. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Cincinnati, OH
- Active Since 06/02/2005
- Last Updated 03/11/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1720080807
Products in Payments
- HYQVIA (Biological) $6,535
- ADVAIR (Drug) $3,000
- Fluticasone Propionate and Salmeterol (Drug) $222.51
- Haegarda (Biological) $26.70
- Xolair (Biological) $22.00
- NIOX VERO DEVICE (Device) $19.22
- CINQAIR (Drug) $15.07
- Gammaplex 10% (Biological) $14.22
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Cincinnati
Dr. Sasidhar Kilaru, M.d, M.D
Specialist — Payments: $37,347
Specialist $37,347
Dr. Sadia Benzaquen, Md, MD
Specialist — Payments: $32,887
Specialist $32,887
Mr. Michael Justin, M.d, M.D
Specialist — Payments: $31,478
Specialist $31,478
Dr. Peter Stern, M.d, M.D
Specialist — Payments: $25,597
Specialist $25,597
Peter Mckenna, M.d, M.D
Specialist — Payments: $15,168
Specialist $15,168
Andrew Duker, Md, MD
Specialist — Payments: $9,061
Specialist $9,061